Please use this identifier to cite or link to this item:
|Title:||Exploiting lymphatic transport and complement activation in nanoparticle vaccines||Authors:||Reddy, S.T.
Van Der Vlies, A.J.
|Issue Date:||Oct-2007||Citation:||Reddy, S.T., Van Der Vlies, A.J., Simeoni, E., Angeli, V., Randolph, G.J., O'Neil, C.P., Lee, L.K., Swartz, M.A., Hubbell, J.A. (2007-10). Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnology 25 (10) : 1159-1164. ScholarBank@NUS Repository. https://doi.org/10.1038/nbt1332||Abstract:||Antigen targeting and adjuvancy schemes that respectively facilitate delivery of antigen to dendritic cells and elicit their activation have been explored in vaccine development. Here we investigate whether nanoparticles can be used as a vaccine platform by targeting lymph node-residing dendritic cells via interstitial flow and activating these cells by in situ complement activation. After intradermal injection, interstitial flow transported ultra-small nanoparticles (25 nm) highly efficiently into lymphatic capillaries and their draining lymph nodes, targeting half of the lymph node-residing dendritic cells, whereas 100-nm nanoparticles were only 10% as efficient. The surface chemistry of these nanoparticles activated the complement cascade, generating a danger signal in situ and potently activating dendritic cells. Using nanoparticles conjugated to the model antigen ovalbumin, we demonstrate generation of humoral and cellular immunity in mice in a size- and complement-dependent manner. © 2007 Nature Publishing Group.||Source Title:||Nature Biotechnology||URI:||http://scholarbank.nus.edu.sg/handle/10635/131541||ISSN:||10870156||DOI:||10.1038/nbt1332|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 25, 2021
WEB OF SCIENCETM
checked on Feb 18, 2021
checked on Feb 27, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.